LATS1 and Alzheimer disease: Levels of O-GlcNAcylation, a post-translational modification that enhances YAP activation by disrupting LATS1/2 phosphorylation and preventing YAP degradation [64, 65], are reduced in AD, possibly due to glucose hypometabolism [184, 185].